Accelerate to discover

Back to filter

Related topics

Cellular stress induces erythrocyte assembly and promotes microangiopathy

Fluxion Biosciences

Dec 19, 2018

Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms...

The need for ultra high field magnetic resonance imaging

Bruker Biospin

Dec 17, 2018

MRI  is a noninvasive imaging technology that is known for its superior soft tissue contrast and ability to provide...

NovoCyte Quanteon webinar: In-depth cell Proliferation through new advances in flow cytometry

Acea Biosciences

Dec 11, 2018

Cell proliferation is one of the most fundamental biological processes in biology. Many of the traditional assays to...

Live-cell labeling of endogenous proteins with nanometer precision by transduced nanobodies

Etaluma

Dec 6, 2018

Accurate labeling of endogenous proteins for advanced light microscopy in living cells remains challenging. Nanobodies...

Dec 19, 2018

Webinar: early detection of metabolic remodeling in pressure overload left ventricle Hypertrophy

Bruker Biospin

Nov 28, 2018

Do you already heard the hypothesis that metabolic changes in the heart may precede and even trigger structural and...

Squaraine fluorophore as a NIR-fluorescent probe for the in vivo detection of diagnostic enzymes

Spectral Instruments Imaging

Nov 19, 2018

An oligo(ethylene glycol)-functionalized squaraine fluorophore has been developed as an NIR-fluorescent probe that can...

IncuCyte neuronal activity assay

Sartorius

Nov 13, 2018

The generation and maturation of neuronal networks are necessary characteristics of neurogenesis, providing...

Dec 19, 2018

The most advanced software for preclinical imaging research

Bruker Biospin

Nov 7, 2018

Modern imaging laboratories hosting PET/MR instruments profit from the fully integrated common imaging platform...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey